Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, Bonet L, Vidal F, Milinkovic A, Bassa A, Villalonga C, Pérez I, Tural C, Martínez-Rebollar M, Calvo M, Blanco JL, Martínez E, Sánchez-Tapias JM, Gatell JM, Mallolas J. Laguno M, et al. Among authors: tural c. Hepatology. 2009 Jan;49(1):22-31. doi: 10.1002/hep.22598. Hepatology. 2009. PMID: 19085908 Clinical Trial.
Prevalence and genotypes of GB virus C/hepatitis G virus (GBV-C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: evidence of GBV-C/HGV sexual transmission.
Ibáñez A, Giménez-Barcons M, Tajahuerce A, Tural C, Sirera G, Clotet B, Sánchez-Tapias JM, Rodés J, Martínez MA, Saiz JC. Ibáñez A, et al. Among authors: tural c. J Med Virol. 1998 Aug;55(4):293-9. doi: 10.1002/(sici)1096-9071(199808)55:4<293::aid-jmv7>3.0.co;2-w. J Med Virol. 1998. PMID: 9661838
Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV.
Puig-Basagoiti F, Cabana M, Guilera M, Giménez-Barcons M, Sirera G, Tural C, Clotet B, Sánchez-Tapias JM, Rodés J, Saiz JC, Martínez MA. Puig-Basagoiti F, et al. Among authors: tural c. J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):89-94. doi: 10.1097/00126334-200001010-00012. J Acquir Immune Defic Syndr. 2000. PMID: 10708061
Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.
Soriano V, Miró JM, García-Samaniego J, Torre-Cisneros J, Núñez M, del Romero J, Martín-Carbonero L, Castilla J, Iribarren JA, Quereda C, Santín M, González J, Arribas JR, Santos I, Hernández-Quero J, Ortega E, Asensi V, del Pozo MA, Berenguer J, Tural C, Clotet B, Leal M, Mallolas J, Sánchez-Tapias JM, Moreno S, Gatell JM, Téllez MJ, Rubio R, Ledesma E, Domingo P, Barreiro P, Pedreira J, Romero M, González-Lahoz J, Lissen E. Soriano V, et al. Among authors: tural c. J Viral Hepat. 2004 Jan;11(1):2-17. doi: 10.1046/j.1365-2893.2003.00491.x. J Viral Hepat. 2004. PMID: 14738553 Review.
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL, Miró O, López S, Fuster D, Videla S, Martínez E, Garrabou G, Salas A, Côté H, Tor J, Rey-Joly C, Planas R, Clotet B, Tural C. Ballesteros AL, et al. Among authors: tural c. Antivir Ther. 2004 Dec;9(6):969-77. Antivir Ther. 2004. PMID: 15651755 Clinical Trial.
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Fuster D, Huertas JA, Gómez G, Solà R, González García J, Vilaró J, Pedrol E, Force L, Tor J, Sirera G, Videla S, Planas R, Clotet B, Tural C; PEG-TOX Research Group. Fuster D, et al. Among authors: tural c. Antivir Ther. 2005;10(7):841-7. Antivir Ther. 2005. PMID: 16312180 Clinical Trial.
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
Solà R, Galeras JA, Montoliu S, Tural C, Force L, Torra S, Montull S, Castro ER, Coll S, Fuster D, Barrufet P, Sirera G, Giménez MD, Clotet B, Planas R. Solà R, et al. Among authors: tural c. AIDS Res Hum Retroviruses. 2006 May;22(5):393-400. doi: 10.1089/aid.2006.22.393. AIDS Res Hum Retroviruses. 2006. PMID: 16706615 Clinical Trial.
257 results